Literature DB >> 20812358

Clinical syndromes and consequences of antiretroviral-related hepatotoxicity.

Marina Núñez1.   

Abstract

Highly active antiretroviral therapy (HAART)-related hepatotoxicity complicates the management of patients infected with human immunodeficiency virus (HIV), increases medical costs, alters the prescription patterns, and affects the guideline recommendations. Among the clinical consequences derived from HAART-related liver toxicity, hypersensitivity reactions and lactic acidosis are recognized as acute events with potential to evolve into fatal cases, whereas there seems to be other syndromes not as well characterized but of equal concern as possible long-term liver complications. Belonging to the latter category of syndrome, HAART-related nonalcoholic steatohepatitis, liver fibrosis, portal hypertension, and nodular regenerative hyperplasia are discussed in this review. Updated information on liver toxicity of current antiretroviral drugs, including the most recently licensed, is provided. Management and prevention of liver toxicity among HIV-infected patients treated with HAART are reviewed as well.

Entities:  

Mesh:

Year:  2010        PMID: 20812358     DOI: 10.1002/hep.23716

Source DB:  PubMed          Journal:  Hepatology        ISSN: 0270-9139            Impact factor:   17.425


  41 in total

Review 1.  Idiosyncratic drug-induced liver injury: a clinical update.

Authors:  Haripriya Maddur; Naga Chalasani
Journal:  Curr Gastroenterol Rep       Date:  2011-02

2.  Liver Function Tests Abnormalities and Hepatitis B Virus & Hepatitis C Virus Co-infection in Human Immunodeficiency Virus (HIV)-infected Patients in India.

Authors:  P Puri; P K Sharma; A Lolusare; V K Sashindran; S Shrivastava; A K Nagpal
Journal:  J Clin Exp Hepatol       Date:  2016-12-29

3.  Nonalcoholic Steatohepatitis and Hepatic Fibrosis in HIV-1-Monoinfected Adults With Elevated Aminotransferase Levels on Antiretroviral Therapy.

Authors:  Caryn G Morse; Mary McLaughlin; Lindsay Matthews; Michael Proschan; Francine Thomas; Ahmed M Gharib; Mones Abu-Asab; Abigail Orenstein; Ronald E Engle; Xiaojun Hu; Richard Lempicki; Colleen Hadigan; David E Kleiner; Theo Heller; Joseph A Kovacs
Journal:  Clin Infect Dis       Date:  2015-02-13       Impact factor: 9.079

Review 4.  Novel cell and gene therapies for HIV.

Authors:  James A Hoxie; Carl H June
Journal:  Cold Spring Harb Perspect Med       Date:  2012-10-01       Impact factor: 6.915

5.  Generation of an HIV-1-resistant immune system with CD34(+) hematopoietic stem cells transduced with a triple-combination anti-HIV lentiviral vector.

Authors:  Jon E Walker; Rachel X Chen; Jeannine McGee; Catherine Nacey; Richard B Pollard; Mehrdad Abedi; Gerhard Bauer; Jan A Nolta; Joseph S Anderson
Journal:  J Virol       Date:  2012-03-07       Impact factor: 5.103

6.  A cross-sectional study of liver function tests in HIV-infected persons in Western India.

Authors:  Sunny Pathania; Navjyot Kaur; Sandeep Kumar; V K Sashindran; Pankaj Puri
Journal:  Med J Armed Forces India       Date:  2017-01-07

7.  Antitubercular therapy induced liver function tests abnormalities in human immunodeficiency virus infected individuals.

Authors:  Pankaj Puri; Navjyot Kaur; Sunny Pathania; Sandeep Kumar; P K Sharma; V K Sashindran
Journal:  Med J Armed Forces India       Date:  2017-01-07

Review 8.  Human immunodeficiency virus and nodular regenerative hyperplasia of liver: A systematic review.

Authors:  Archita Sood; Mariana Castrejón; Sammy Saab
Journal:  World J Hepatol       Date:  2014-01-27

Review 9.  Acute hepatitis C in an HIV-infected patient: a case report and review of literature.

Authors:  Todd H Driver; Norah Terrault; Varun Saxena
Journal:  J Gen Intern Med       Date:  2012-11-14       Impact factor: 5.128

10.  Brief Report: Highly Active Antiretroviral Therapy Mitigates Liver Disease in HIV Infection.

Authors:  Jennifer C Price; Eric C Seaberg; John P Phair; Mallory D Witt; Susan L Koletar; Chloe L Thio
Journal:  J Acquir Immune Defic Syndr       Date:  2016-07-01       Impact factor: 3.731

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.